Efficacy of Bailing capsule for autoimmune antibodies in Hashimoto thyroiditis: a meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

LIU Yangqing ¹ ,  WANG Yanfang ² , GUO Lijun ³

1. Henan University People's Hospital, Zhengzhou 450003, P.R.China;
2. Department of Endocrinology, Henan Provincial People’s Hospital, Zhengzhou 450003, P.R.China;
3. Jinzhou Medical University, Jinzhou 121000, P.R.China;

Corresponding?author：

WANG Yanfang, Email: yfwang612@126.com

Keywords：

Bailing capsule; Hashimoto thyroiditis; Autoimmune antibodies; Meta-analysis; Systematic review; Randomized controlled trial

DOI：

10.7507/1672-2531.201904064

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To systematically review the efficacy of Bailing capsule for autoimmune antibodies in Hashimoto thyroiditis (HT).Methods PubMed, EMbase, The Cochrane Library, CBM, WanFang Data and CNKI databases were electronically searched to collect the randomized controlled trials (RCTs) on Bailing capsule in treatment of HT from inception to January 2019. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, then, meta-analysis was performed by using RevMan 5.3 software.Results A total of 7 RCTs involving 428 patients were included. The results of meta-analysis showed that the changes of TGAb and TPOAb in Bailing capsule combined with Euthyrox group were higher than that in control group (MD=?228.91, 95%CI ?398.61 to ?59.20, P=0.008; MD=?158.19, 95%CI ?222.44 to ?93.94, P<0.000 01); the changes of TGAb and TPOAb in Bailing capsule combined with Iodine modification diet group were higher than that in control group(MD=?499.27, 95%CI ?540.39 to ?458.15, P<0.000 01; MD=?407.37, 95%CI ?448.60 to ?366.14, P<0.000 01).Conclusions Current evidence shows that Bailing capsule combined with other therapies can decrease the levels of TGAb and TPOAb in HT patients. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusion.

Citation： LIU Yangqing, WANG Yanfang, GUO Lijun. Efficacy of Bailing capsule for autoimmune antibodies in Hashimoto thyroiditis: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2020, 20(4): 453-457. doi: 10.7507/1672-2531.201904064 Copy

1.	Semiz H, Yalcin M, Kobak S. Coexistence of sarcoidosis and Hashimoto thyroiditis. Reumatismo, 2018, 70(2): 106-110.
2.	Abbott RD, Sadowski A, Alt AG. Efficacy of the autoimmune protocol diet as part of a multi-disciplinary, supported lifestyle intervention for hashimoto's thyroiditis. Cureus, 2019, 11(4): e4556.
3.	Krysiak R, Kowalcze K, Okopień B. The effect of vitamin D on thyroid autoimmunity in euthyroid men with autoimmune thyroiditis and testosterone deficiency. Pharmacol Rep, 2019, 71(5): 798-803.
4.	中華醫學會內分泌學分會. 中國甲狀腺疾病診治指南—甲狀腺炎. 中華內科雜志, 2008, 47(9): 784-788.
5.	Liu C. Chronic lymphocytic thyroiditis. Int J Endocrinol Metab, 2009, 29(1): 57-59.
6.	Brix TH, Laszlo H. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol, 2012, 76(4): 457-464.
7.	Ren HJ, Sun YL, Yuan B. Chinese patent medicine Bailing capsule for treating lupus nephritis: a protocol for systematic review and meta-analysis. Medicine (Baltimore), 2019, 98(37): e17041.
8.	王新, 王靜. 百令膠囊輔助治療對穩定期 COPD 患者氣道功能及血清氣道重塑分子的影響. 中國現代醫學雜志, 2019, 29(6): 88-91.
9.	祝明, 金樟照, 陳勇, 等. 百令膠囊的指紋圖譜鑒別研究. 中成藥, 2007, 29(9): 1254-1256.
10.	楊立娜, 丁萌, 張翠蘭, 等. 不同劑量百令膠囊聯合左甲狀腺素治療橋本甲狀腺炎的臨床研究. 現代藥物與臨床, 2018, 33(5): 1193-1197.
11.	He T, Zhao R, Lu Y, et al. Dual-directional immunomodulatory effects of Corbin capsule on autoimmune thyroid diseases. Evid Based Complement Alternat Med, 2016, 2016: 1360386.
12.	迪麗卡麥爾·艾沙. 優甲樂聯合硒維爾與百令膠囊對橋本氏甲狀腺炎并甲減患者的 (Anti-TPO, Anti-TG) 抗體水平比較. 南昌: 南昌大學, 2016.
13.	范莉萍. 百令膠囊對橋本氏甲減免疫功能及甲狀腺功能的影響. 長春: 吉林大學, 2014.
14.	劉寶忠, 張花, 楊坤, 等. 百令膠囊對橋本甲狀腺炎患者自身免疫性抗體的影響. 醫藥導報, 2009, 28(6): 727-728.
15.	李淑文. 百令膠囊對橋本甲狀腺炎患者自身免疫性抗體的影響. 中國藥物經濟學, 2017, 12(10): 57-59.
16.	張瑋. 百令膠囊對橋本氏甲狀腺炎患者過氧化物酶抗體的影響. 實用臨床醫學, 2015, 16(4): 23-24.
17.	汪新宇, 王桂蘭, 田志剛. Th1/Th2 亞群與自身免疫性甲狀腺疾病. 中華內分泌代謝雜志, 2001, 17(2): 124-125.
18.	趙閆麗, 黃琦. 橋本甲狀腺炎 Th1/Th2 偏移的研究及治療進展. 浙江中醫藥大學學報, 2014, (1): 107-109.
19.	許崢嶸, 李昭瑛. 橋本甲狀腺炎與 Th1/Th2 細胞因子. 醫學綜述, 2006, 12(24): 1492-1493.
20.	陶征, 吳潔, 李連喜. 自身免疫性甲狀腺疾病甲狀腺自身抗體的臨床研究. 江蘇大學學報 (醫學版), 2004, 14(2): 123-125, 129.
21.	陶靜芬, 朱明風, 葉根娟, 等. 血清 TPOAb 與 TMA、TGA 在橋本氏甲狀腺炎診斷中的臨床意義. 放射免疫學雜志, 2000, 13(5): 299-300.
22.	Stott DJ, Gussekloo J, Kearney PM, et al. Study protocol: thyroid hormone replacement for untreated older adults with subclinical hypothyroidism-a randomised placebo controlled trial (TRUST). BMC Endocr Disord, 2017, 17(1): 6.
23.	韓靜, 劉守堯. 橋本氏甲狀腺炎中西醫治療研究進展. 中華中醫藥雜志, 2019, 34(11): 5327-5330.
24.	孫忠華, 肖建輝. 蟲草屬真菌的生物活性. 中藥材, 2013, 36(7): 1183-1189.
25.	許惠娟, 李時悅. 百令膠囊的藥理作用及其在肺部疾病的研究進展. 中國中藥雜志, 2010, 35(20): 2777-2781.
26.	李曉雯, 廖春分, 陳思思, 等. 百令膠囊口服聯合曲安奈德局部注射治療橋本氏甲狀腺炎的療效觀察. 中南醫學科學雜志, 2016, 44(3): 319-322.

1. Semiz H, Yalcin M, Kobak S. Coexistence of sarcoidosis and Hashimoto thyroiditis. Reumatismo, 2018, 70(2): 106-110.
2. Abbott RD, Sadowski A, Alt AG. Efficacy of the autoimmune protocol diet as part of a multi-disciplinary, supported lifestyle intervention for hashimoto's thyroiditis. Cureus, 2019, 11(4): e4556.
3. Krysiak R, Kowalcze K, Okopień B. The effect of vitamin D on thyroid autoimmunity in euthyroid men with autoimmune thyroiditis and testosterone deficiency. Pharmacol Rep, 2019, 71(5): 798-803.
4. 中華醫學會內分泌學分會. 中國甲狀腺疾病診治指南—甲狀腺炎. 中華內科雜志, 2008, 47(9): 784-788.
5. Liu C. Chronic lymphocytic thyroiditis. Int J Endocrinol Metab, 2009, 29(1): 57-59.
6. Brix TH, Laszlo H. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol, 2012, 76(4): 457-464.
7. Ren HJ, Sun YL, Yuan B. Chinese patent medicine Bailing capsule for treating lupus nephritis: a protocol for systematic review and meta-analysis. Medicine (Baltimore), 2019, 98(37): e17041.
8. 王新, 王靜. 百令膠囊輔助治療對穩定期 COPD 患者氣道功能及血清氣道重塑分子的影響. 中國現代醫學雜志, 2019, 29(6): 88-91.
9. 祝明, 金樟照, 陳勇, 等. 百令膠囊的指紋圖譜鑒別研究. 中成藥, 2007, 29(9): 1254-1256.
10. 楊立娜, 丁萌, 張翠蘭, 等. 不同劑量百令膠囊聯合左甲狀腺素治療橋本甲狀腺炎的臨床研究. 現代藥物與臨床, 2018, 33(5): 1193-1197.
11. He T, Zhao R, Lu Y, et al. Dual-directional immunomodulatory effects of Corbin capsule on autoimmune thyroid diseases. Evid Based Complement Alternat Med, 2016, 2016: 1360386.
12. 迪麗卡麥爾·艾沙. 優甲樂聯合硒維爾與百令膠囊對橋本氏甲狀腺炎并甲減患者的 (Anti-TPO, Anti-TG) 抗體水平比較. 南昌: 南昌大學, 2016.
13. 范莉萍. 百令膠囊對橋本氏甲減免疫功能及甲狀腺功能的影響. 長春: 吉林大學, 2014.
14. 劉寶忠, 張花, 楊坤, 等. 百令膠囊對橋本甲狀腺炎患者自身免疫性抗體的影響. 醫藥導報, 2009, 28(6): 727-728.
15. 李淑文. 百令膠囊對橋本甲狀腺炎患者自身免疫性抗體的影響. 中國藥物經濟學, 2017, 12(10): 57-59.
16. 張瑋. 百令膠囊對橋本氏甲狀腺炎患者過氧化物酶抗體的影響. 實用臨床醫學, 2015, 16(4): 23-24.
17. 汪新宇, 王桂蘭, 田志剛. Th1/Th2 亞群與自身免疫性甲狀腺疾病. 中華內分泌代謝雜志, 2001, 17(2): 124-125.
18. 趙閆麗, 黃琦. 橋本甲狀腺炎 Th1/Th2 偏移的研究及治療進展. 浙江中醫藥大學學報, 2014, (1): 107-109.
19. 許崢嶸, 李昭瑛. 橋本甲狀腺炎與 Th1/Th2 細胞因子. 醫學綜述, 2006, 12(24): 1492-1493.
20. 陶征, 吳潔, 李連喜. 自身免疫性甲狀腺疾病甲狀腺自身抗體的臨床研究. 江蘇大學學報 (醫學版), 2004, 14(2): 123-125, 129.
21. 陶靜芬, 朱明風, 葉根娟, 等. 血清 TPOAb 與 TMA、TGA 在橋本氏甲狀腺炎診斷中的臨床意義. 放射免疫學雜志, 2000, 13(5): 299-300.
22. Stott DJ, Gussekloo J, Kearney PM, et al. Study protocol: thyroid hormone replacement for untreated older adults with subclinical hypothyroidism-a randomised placebo controlled trial (TRUST). BMC Endocr Disord, 2017, 17(1): 6.
23. 韓靜, 劉守堯. 橋本氏甲狀腺炎中西醫治療研究進展. 中華中醫藥雜志, 2019, 34(11): 5327-5330.
24. 孫忠華, 肖建輝. 蟲草屬真菌的生物活性. 中藥材, 2013, 36(7): 1183-1189.
25. 許惠娟, 李時悅. 百令膠囊的藥理作用及其在肺部疾病的研究進展. 中國中藥雜志, 2010, 35(20): 2777-2781.
26. 李曉雯, 廖春分, 陳思思, 等. 百令膠囊口服聯合曲安奈德局部注射治療橋本氏甲狀腺炎的療效觀察. 中南醫學科學雜志, 2016, 44(3): 319-322.

Chinese Journal of Evidence-Based Medicine

Efficacy of Bailing capsule for autoimmune antibodies in Hashimoto thyroiditis: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content